Last reviewed 2026-04-23 · How we verify

FOY-305

FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events.

FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events. Used for Thrombotic disorders (investigational).

At a glance

Mechanism of action

FOY-305 directly inhibits Factor IIa (thrombin), a key serine protease in the blood coagulation cascade. By blocking thrombin activity, the drug reduces thrombin generation and fibrin formation, thereby preventing pathological blood clot formation. This mechanism is intended to provide anticoagulant effects for thrombotic disease prevention.

Approved indications

• Thrombotic disorders (investigational)

Common side effects

• Bleeding
• Gastrointestinal hemorrhage

Key clinical trials

• The Impact of Camostat Mesilate on COVID-19 Infection (PHASE1, PHASE2)
• Effect Camostat for Kidney Protection in Chronic Kidney Disease (PHASE2)
• Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation (PHASE2)
• Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (PHASE2)
• The Potential of Camostat in COVID-19 (PHASE2)
• ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2, PHASE3)
• Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects (PHASE1)
• A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• FOY-305 CI brief — competitive landscape report
• FOY-305 updates RSS · CI watch RSS
• Ono Pharmaceutical Co. Ltd portfolio CI